Article

Aspirin-induced peptic ulcer and genetic polymorphisms

Department of Internal Medicine, Kawasaki Medical School, Matsushima Kurashiki City, Okayama, Japan.
Journal of Gastroenterology and Hepatology (Impact Factor: 3.63). 05/2010; 25 Suppl 1:S31-4. DOI: 10.1111/j.1440-1746.2009.06212.x
Source: PubMed

ABSTRACT There are a few studies of the association between genetic polymorphisms and the risks of acetylsalicylic acid (aspirin)-induced ulcer or its complications. Two single nucleotide polymorphisms (SNP) of cyclooxygenase-1 (COX-1), A-842G and C50T, exhibited increased sensitivity to aspirin and had lower prostaglandin synthesis capacity, lacking statistical significance in the association with bleeding peptic ulcer. A recent Japanese study indicated that the number of COX-1-1676T alleles was a significant risk factor for peptic ulcer in users of non-steroidal anti-inflammatory drugs (NSAIDs). There are some genetic polymorphisms for aspirin resistance, such as platelet membrane glycoproteins, thromboxane A2 (TXA2) receptor, platelet activating factor acetylhydrolase and coagulation factor XIII; however, data on the frequency of gastrointestinal (GI) events in these variants are lacking. Carrying the CYP2C9 variants is reported a significantly increased risk of non-aspirin NSAID-related GI bleeding. The polymorphisms of interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) have been associated with development of peptic ulcer or gastric cancer. In a recent investigation, carriage of the IL-1beta-511 T allele was significantly associated with peptic ulcer among low-dose aspirin users. Hypoacidity in corpus gastritis related to polymorphisms of pro-inflammatory cytokines seems to reduce NSAIDs or aspirin-related injury. Data on which polymorphisms are significant risk factors for GI events in aspirin users are still lacking and further large-scale clinical studies are required.

Download full-text

Full-text

Available from: Akiko Shiotani, Sep 19, 2014
0 Followers
 · 
92 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are a few studies of the association between genetic polymorphisms and the risks of acetylsalicylic acid (aspirin)-induced ulcer or its complications. Two single nucleotide polymorphisms (SNP) of cyclooxygenase-1 (COX-1), A-842G and C50T, exhibited increased sensitivity to aspirin and had lower prostaglandin synthesis capacity, lacking statistical significance in the association with bleeding peptic ulcer. A recent Japanese study indicated that the number of COX-1-1676T alleles was a significant risk factor for peptic ulcer in users of non-steroidal anti-inflammatory drugs (NSAIDs). There are some genetic polymorphisms for aspirin resistance, such as platelet membrane glycoproteins, thromboxane A2 (TXA2) receptor, platelet activating factor acetylhydrolase and coagulation factor XIII; however, data on the frequency of gastrointestinal (GI) events in these variants are lacking. Carrying the CYP2C9 variants is reported a significantly increased risk of non-aspirin NSAID-related GI bleeding. The polymorphisms of interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) have been associated with development of peptic ulcer or gastric cancer. In a recent investigation, carriage of the IL-1beta-511 T allele was significantly associated with peptic ulcer among low-dose aspirin users. Hypoacidity in corpus gastritis related to polymorphisms of pro-inflammatory cytokines seems to reduce NSAIDs or aspirin-related injury. Data on which polymorphisms are significant risk factors for GI events in aspirin users are still lacking and further large-scale clinical studies are required.
    Journal of Gastroenterology and Hepatology 05/2010; 25 Suppl 1:S31-4. DOI:10.1111/j.1440-1746.2009.06212.x · 3.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiplatelet therapy represents the cornerstone of treatment for the short- and long-term prevention of atherothrombotic disease processes, in particular in high-risk settings such as in patients with acute coronary syndrome and those undergoing percutaneous coronary intervention. Currently, dual antiplatelet therapy with aspirin and clopidogrel represents the most commonly used treatment regimen in these settings. However, a considerable number of patients continue to experience adverse outcomes, including both bleeding and recurrent ischemic events. Numerous investigations have demonstrated that this phenomenon may be, in part, attributed to the broad variability in individual response profiles to this standard antiplatelet treatment regimen, as identified by various assays of platelet function testing. In addition, recent studies have demonstrated that genetic polymorphisms may also have an important role in determining levels of platelet inhibition and may be considered as a tool to identify patients at risk of adverse events. This article provides an overview on antiplatelet drug response variability, an update on definitions, including the role of pharmacodynamic testing, underlying mechanisms - with emphasis on recent understandings on pharmacogenetics and drug-drug interactions - and current and future perspectives on individualized antiplatelet therapy.
    Future Cardiology 05/2011; 7(3):381-402. DOI:10.2217/fca.11.14
  • [Show abstract] [Hide abstract]
    ABSTRACT: The existence of genetic polymorphisms in metabolizing enzymes can be regarded as one of the principal causes of interindividual variation in response to drugs and adverse reactions. In the case of enzyme CYP2C9, the presence of genetic coding variants could be considered a risk factor for suffering from gastrointestinal haemorrhages associated with the use of nonsteroidal anti-inflammatory drugs, due to a reduction in the enzyme's rate of metabolism. The aim of this study was to conduct a systematic critical review aimed at assessing whether the presence of CYP2C9*2 and CYP2C9*3 could increase the risk of suffering from gastrointestinal haemorrhages due to nonsteroidal anti-inflammatory drug use. Using MEDLINE as the data source, the search was limited to scientific studies published in English. Six studies met the inclusion criteria, whereas three reported no results because there were no homozygous mutant genotypes for CYP2C9*2 and *3 in their samples, risk of bleeding was associated by one with the presence of CYP2C9*2 and by two with the CYP2C9*3 coding variant. Some of the studies included in this review contained methodological limitations, which prevented the increased risk of suffering gastrointestinal haemorrhages due to nonsteroidal anti-inflammatory drug use from being satisfactorily linked to the presence of CYP2C9 coding variants.
    Pharmacogenetics and Genomics 07/2011; 21(7):357-64. DOI:10.1097/FPC.0b013e328346d2bb · 3.45 Impact Factor
Show more